|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quoix E, Lena H, Losonczy G, Forget F,
Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A and
Kazarnowicz A: TG4010 immunotherapy and first-line chemotherapy for
advanced non-small-cell lung cancer (TIME): Results from the phase
2b part of a randomised, double-blind, placebo-controlled, phase
2b/3 trial. Lancet Oncol. 17:212–223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pinato DJ, Shiner RJ, White SD, Black JR,
Trivedi P, Stebbing J, Sharma R and Mauri FA: Intra-tumoral
heterogeneity in the expression of programmed-death (PD) ligands in
isogeneic primary and metastatic lung cancer: Implications for
immunotherapy. Oncoimmunology. 5:e12139342016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coulie PG, Van den Eynde BJ, van der
Bruggen P and Boon T: Tumour antigens recognized by T lymphocytes:
At the core of cancer immunotherapy. Nat Rev Cancer. 14:135–146.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ulloa-Montoya F, Louahed J, Dizier B,
Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont
AM, Vansteenkiste J and Brichard VG: Predictive gene signature in
MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol.
31:2388–2395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rao M, Chinnasamy N, Hong JA, Zhang Y,
Zhang M, Xi S, Liu F, Marquez VE, Morgan RA and Schrump DS:
Inhibition of histone lysine methylation enhances cancer-testis
antigen expression in lung cancer cells: Implications for adoptive
immunotherapy of cancer. Cancer Res. 71:4192–4204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dobrynin P, Matyunina E, Malov SV and
Kozlov AP: The novelty of human cancer/testis antigen encoding
genes in evolution. Int J Genomics. 2013:1051082013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gure AO, Chua R, Williamson B, Gonen M,
Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and
Altorki NK: Cancer-testis genes are coordinately expressed and are
markers of poor outcome in non-small cell lung cancer. Clin Cancer
Res. 11:8055–8062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koop A, Sellami N, Adam-Klages S, Lettau
M, Kabelitz D, Janssen O and Heidebrecht HJ: Down-regulation of the
cancer/testis antigen 45 (CT45) is associated with altered tumor
cell morphology, adhesion and migration. Cell Commun Signal.
11:412013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caballero OL, Cohen T, Gurung S, Chua R,
Lee P, Chen YT, Jat P and Simpson AJ: Effects of CT-Xp gene knock
down in melanoma cell lines. Oncotarget. 4:531–541. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andrade VC, Vettore AL, Silva MR Regis,
Felix RS, Almeida MS, de Carvalho F, Zago MA, Caballero OL, Simpson
AJ and Colleoni GW: Frequency and prognostic relevance of cancer
testis antigen 45 expression in multiple myeloma. Exp Hematol.
37:446–449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gotoh K, Yatabe Y, Sugiura T, Takagi K,
Ogawa M, Takahashi T, Takahashi T and Mitsudomi T: Frequency of
MAGE-3 gene expression in HLA-A2 positive patients with non-small
cell lung cancer. Lung Cancer. 20:117–125. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yanagawa N, Tamura G, Oizumi H, Endoh M
and Motoyama T: MAGE mediated by demethylation of MAGE promoters
induce progression of non-small cell lung cancer. Anticancer Res.
31:171–175. 2011.PubMed/NCBI
|
|
16
|
Sienel W, Varwerk C, Linder A, Kaiser D,
Teschner M, Delire M, Stamatis G and Passlick B: Melanoma
associated antigen (MAGE)-A3 expression in Stages I and II
non-small cell lung cancer: Results of a multi-center study. Eur J
Cardiothorac Surg. 25:131–134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tajima K, Obata Y, Tamaki H, Yoshida M,
Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Takahashi T and
Mitsudomi T: Expression of cancer/testis (CT) antigens in lung
cancer. Lung Cancer. 42:23–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fourcade J, Sun Z, Pagliano O, Chauvin JM,
Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S,
et al: PD-1 and Tim-3 regulate the expansion of tumor
antigen-specific CD8+ T cells induced by melanoma
vaccines. Cancer Res. 74:1045–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eikawa S, Kakimi K, Isobe M, Kuzushima K,
Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, et
al: Induction of CD8 T-cell responses restricted to multiple HLA
class I alleles in a cancer patient by immunization with a 20-mer
NY-ESO-1f (NY-ESO-1 91–110) peptide. Int J Cancer. 132:345–354.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cerfolio RJ and Bryant AS: Optimal care of
patients with non-small cell lung cancer reduces perioperative
morbidity. J Thorac Cardiovasc Surg. 141:22–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Smet C and Loriot A: DNA
hypomethylation and activation of germline-specific genes in
cancer. Adv Exp Med Biol. 754:149–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Carvalho F, Alves VL, Braga WM, Xavier
CV Jr and Colleoni GW: MAGE-C1/CT7 and MAGE-C2/CT10 are frequently
expressed in multiple myeloma and can be explored in combined
immunotherapy for this malignancy. Cancer Immunol Immunother.
62:191–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brichard VG and Godechal Q:
MAGE-A3-specific anticancer immunotherapy in the clinical practice.
Oncoimmunology. 2:e259952013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pabst C, Zustin J, Jacobsen F, Luetkens T,
Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D and
Marx A: Expression and prognostic relevance of MAGE-C1/CT7 and
MAGE-C2/CT10 in osteolytic lesions of patients with multiple
myeloma. Exp Mol Pathol. 89:175–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Straetemans T, van Brakel M, van
Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN,
Lamers C, van Der Bruggen P, Coulie PG and Debets R: TCR gene
transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as
melanoma-specific immune targets. Clin Dev Immunol.
2012:5863142012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma W, Germeau C, Vigneron N, Maernoudt AS,
Morel S, Boon T, Coulie PG and Van den Eynde BJ: Two new
tumor-specific antigenic peptides encoded by gene MAGE-C2 and
presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer.
109:698–702. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Sun Z, Nicolay H, Meyer RG,
Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM,
Marchand M, et al: Monitoring of anti-vaccine CD4 T cell
frequencies in melanoma patients vaccinated with a MAGE-3 protein.
J Immunol. 174:2404–2411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olarte I, Martinez A, Ramos-Peñafiel C,
Castellanos-Sinco H, Zamora J, Collazo-Jaloma J, Gutiérrez M,
Gutiérrez-Kobeh L, Chavez-Olmos P, Manzanilla H, et al: MAGE-A3
expression is an adverse prognostic factor in diffuse large B-cell
lymphoma. Hematology. 16:368–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riener MO, Wild PJ, Soll C, Knuth A, Jin
B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H and Jochum W:
Frequent expression of the novel cancer testis antigen
MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer.
124:352–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Detterbeck FC, Postmus PE and Tanoue LT:
The stage classification of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American college of chest physicians
evidence-based clinical practice guidelines. Chest. 143(5): Suppl.
e191S–e210S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rapoport AP, Stadtmauer EA, Binder-Scholl
GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B,
Finklestein J, et al: NY-ESO-1-specific TCR-engineered T cells
mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med. 21:914–921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hofmann O, Caballero OL, Stevenson BJ,
Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A,
et al: Genome-wide analysis of cancer/testis gene expression. Proc
Natl Acad Sci USA. 105:20422–20427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Caballero OL and Chen YT: Cancer/testis
(CT) antigens: Potential targets for immunotherapy. Cancer Sci.
100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoshida N, Abe H, Ohkuri T, Wakita D, Sato
M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H and
Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis
antigens and T cell infiltration in non-small cell lung carcinoma
and their prognostic significance. Int J Oncol. 28:1089–1098.
2006.PubMed/NCBI
|
|
38
|
Kim YD, Park HR, Song MH, Shin DH, Lee CH,
Lee MK and Lee SY: Pattern of cancer/testis antigen expression in
lung cancer patients. Int J Mol Med. 29:656–662. 2012.PubMed/NCBI
|
|
39
|
Pineda CT, Ramanathan S, Fon Tacer K, Weon
JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by
a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vaughan HA, Svobodova S, Macgregor D,
Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT,
Stockert E, et al: Immunohistochemical and molecular analysis of
human melanomas for expression of the human cancer-testis antigens
NY-ESO-1 and LAGE-1. Clin Cancer Res. 10:8396–8404. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang
Y and Gu J: Expression profile of cancer-testis genes in 121 human
colorectal cancer tissue and adjacent normal tissue. Clin Cancer
Res. 11:1809–1814. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baia GS, Caballero OL, Ho JS, Zhao Q,
Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A,
Olivi A, et al: NY-ESO-1 expression in meningioma suggests a
rationale for new immunotherapeutic approaches. Cancer Immunol Res.
1:296–302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grah J, Samija M, Juretić A, Sarcević B
and Sobat H: Immunohystochemical expression of cancer/testis
antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: The
relationship with clinical-pathological features. Coll Antropol.
32:731–736. 2008.PubMed/NCBI
|
|
44
|
Tan Q, Wang G, Huang J, Ding Z, Luo Q, Mok
T, Tao Q and Lu S: Epigenomic analysis of lung adenocarcinoma
reveals novel DNA methylation patterns associated with smoking.
Onco Targets Ther. 6:1471–1479. 2013.PubMed/NCBI
|
|
45
|
Bhutani M, Pathak AK, Tang H, Fan YH, Liu
DD, Lee JJ, Kurie J, Morice RC, Hong WK and Mao L: Frequent
expression of MAGE1 tumor antigens in bronchial epithelium of
smokers without lung cancer. Exp Ther Med. 2:137–142.
2011.PubMed/NCBI
|
|
46
|
Chen RJ, Chang LW, Lin P and Wang YJ:
Epigenetic effects and molecular mechanisms of tumorigenesis
induced by cigarette smoke: An overview. J Oncol. 2011:6549312011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Park SY, Lee JG, Kim J, Bae MK, Lee CY,
Kim DJ and Chung KY: The influence of smoking intensity on the
clinicopathologic features and survival of patients with surgically
treated non-small cell lung cancer. Lung Cancer. 81:480–486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang F, Zhou X, Miao X, Zhang T, Hang X,
Tie R, Liu N, Tian F, Wang F and Yuan J: MAGEC2, an
epithelial-mesenchymal transition inducer, is associated with
breast cancer metastasis. Breast Cancer Res Treat. 145:23–32. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen X, Wang L, Yue D, Liu J, Huang L,
Yang L, Cao L, Qin G, Li A, Wang D, et al: Correlation between the
high expression levels of cancer-germline genes with clinical
characteristics in esophageal squamous cell carcinoma. Histol
Histopathol. 118472016.PubMed/NCBI
|
|
50
|
Andrade VC, Vettore AL, Felix RS, Almeida
MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero
OL, Zago MA and Colleoni GW: Prognostic impact of cancer/testis
antigen expression in advanced stage multiple myeloma patients.
Cancer Immun. 8:22008.PubMed/NCBI
|
